CA3219960A1 - Compositions and methods for treating lung cancer - Google Patents

Compositions and methods for treating lung cancer

Info

Publication number
CA3219960A1
CA3219960A1 CA3219960A CA3219960A CA3219960A1 CA 3219960 A1 CA3219960 A1 CA 3219960A1 CA 3219960 A CA3219960 A CA 3219960A CA 3219960 A CA3219960 A CA 3219960A CA 3219960 A1 CA3219960 A1 CA 3219960A1
Authority
CA
Canada
Prior art keywords
antibody
seq
amino acid
acid sequence
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219960A
Other languages
English (en)
French (fr)
Inventor
III Anthony JARKOWSKI
Phillip Dennis
Leo TRANI
Michael Newton
Norah SHIRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA3219960A1 publication Critical patent/CA3219960A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3219960A 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer Pending CA3219960A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192217P 2021-05-24 2021-05-24
US63/192,217 2021-05-24
PCT/EP2022/064061 WO2022248478A1 (en) 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer

Publications (1)

Publication Number Publication Date
CA3219960A1 true CA3219960A1 (en) 2022-12-01

Family

ID=82100132

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219960A Pending CA3219960A1 (en) 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer

Country Status (11)

Country Link
US (1) US20240254235A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347038A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521105A (cg-RX-API-DMAC7.html)
KR (1) KR20240012413A (cg-RX-API-DMAC7.html)
CN (1) CN117425493A (cg-RX-API-DMAC7.html)
AU (1) AU2022281992A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023833A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219960A1 (cg-RX-API-DMAC7.html)
IL (1) IL308530A (cg-RX-API-DMAC7.html)
TW (1) TW202313107A (cg-RX-API-DMAC7.html)
WO (1) WO2022248478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025529196A (ja) * 2022-09-01 2025-09-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 間葉系上皮転換因子(met)標的薬を使用して非小細胞肺がんを治療する方法
EP4694872A1 (en) * 2023-04-14 2026-02-18 Astrazeneca AB Treatment of non-small cell lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US20190276543A1 (en) * 2018-03-08 2019-09-12 Astrazeneca Pharmaceuticals Lp Compositions and methods for treating late stage lung cancer
JP2021523879A (ja) * 2018-03-08 2021-09-09 アストラゼネカ アクチボラグ 後期肺癌の処置のための組成物及び方法
US20230338521A1 (en) * 2020-05-04 2023-10-26 Merck Sharp & Dohme Llc Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor

Also Published As

Publication number Publication date
TW202313107A (zh) 2023-04-01
EP4347038A1 (en) 2024-04-10
CN117425493A (zh) 2024-01-19
JP2024521105A (ja) 2024-05-28
WO2022248478A1 (en) 2022-12-01
KR20240012413A (ko) 2024-01-29
BR112023023833A2 (pt) 2024-01-30
US20240254235A1 (en) 2024-08-01
IL308530A (en) 2024-01-01
AU2022281992A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US20230013642A1 (en) Toxicity Management for Anti-Tumor Activity of CARs
AU2019314452B2 (en) Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof
US20240254235A1 (en) Compositions and methods for treating lung cancer
US20220073622A1 (en) Compositions and Methods for Treating Late Stage Lung Cancer
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
HK1253365B (en) Toxicity management for anti-tumor activity of cars
EA041322B1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car)

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260113